Search
Now showing items 91-96 of 96
Development of biomarker assays to dissect subtype-specific heterogeneity and anti-EGFR treatment response in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-08-31)
Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer and the second leading cause of cancer deaths worldwide. Although extensive biological heterogeneity at multiple "-omics" levels has been ...
Development of novel therapeutic strategies in relapsed advanced/metastatic non-small cell lung cancer
(Institute of Cancer Research (University Of London), 2022-02-28)
Recent advances in the treatment of advanced NSCLC include introduction of targeted therapies and immune-checkpoint inhibitors, leading to improvements in survival outcomes. However, significant new challenges and questions ...
Characterizing the metabolic fate of (2S, 4R)-4-[18F]fluoroglutamine and its applications in cancer imaging and treatment response monitoring
(Institute of Cancer Research (University Of London), 2021-01-31)
Glutaminolysis is a crucial pathway to provide the nitrogen source in addition to the carbon source from the glycolysis pathway for proliferating cells. (2S, 4R)-4-[18F]fluoroglutamine (4-[18F]fluoroglutamine) is potentially ...
Genetics of relapse and treatment resistance in multiple myeloma
(Institute of Cancer Research (University Of London), 2022-05-31)
Better understanding of the mechanisms of relapse and treatment resistance in myeloma could improve clinical outcomes. Copy number aberrations (CNA) are a major feature of multiple myeloma, however their evolution over ...
Next generation circulating tumour DNA detection and subclonality analysis for gastrointestinal cancer therapy personalisation
(Institute of Cancer Research (University Of London), 2021-05-31)
Background: Gastrointestinal cancers are associated with poor outcomes as many patients present with advanced disease. Intratumour heterogeneity (ITH) is a major barrier to predicting the evolution of cancers and successful ...
Phospho-proteomics and functional genomics for the characterisation of resistance mechanisms to agents targeting the EGFR, PI3K and MAPK pathways and their application in guiding drug combinations in colorectal cancer
(Institute of Cancer Research (University Of London), 2019-12-31)
KRAS mutant and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) cells respond differently to targeted agents, as exemplified by cetuximab, an anti-EGFR antibody, which is only effective in a proportion of patients with ...